Novel immunotherapeutic approaches to the treatment of urothelial carcinoma | Zendy

Akhil Muthigi | Zendy; Arvin K. George | Zendy; Sam J. Brancato | Zendy; Piyush K. Agarwal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel immunotherapeutic approaches to the treatment of urothelial carcinoma

Author(s) -

Akhil Muthigi,

Arvin K. George,

Sam J. Brancato,

Piyush K. Agarwal

Publication year - 2016

Publication title -

therapeutic advances in urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.115

H-Index - 30

eISSN - 1756-2880

pISSN - 1756-2872

DOI - 10.1177/1756287216628784

Subject(s) - medicine , immunotherapy , oncolytic virus , monoclonal antibody , bladder cancer , population , immunology , oncology , cancer , cancer research , antibody , environmental health

Immunotherapy has long played a role in urothelial cancers with the use of bacille Calmette Guérin (BCG) being a mainstay in the treatment of nonmuscle invasive bladder cancer. Novel therapeutic approaches have not significantly impacted mortality in this population and so a renaissance in immunotherapy has resulted. This includes recombinant BCG, oncolytic viruses, monoclonal antibodies, vaccines, and adoptive T-cell therapy. Herein, we provide a review of the current state of the art and future therapies regarding immunotherapeutic strategies for urothelial carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research